Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-05-15. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: donorchemotherapycellscellpatients must
  Phrases that lowered it: myelomamultiplehealthypatients whopatients with
• Sponsor's past termination rate: 1.4% (lowers risk) · Sponsor's track record
• Minimum age: 21 (lowers risk) · Who can join
• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports with a death: 36.7% (raises risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: not given (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 77 (lowers risk) · Sponsor's track record
• Sponsor's past trials: 277 (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports marked serious: 96.6% (raises risk) · Drug's FDA history
• Collaborators: 2 (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Maximum age: 72 (lowers risk) · Who can join
• Responsible party: sponsor (lowers risk) · Design
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history
• Disease area, dermatology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01028716 · started 2010 · scored riskier than 58% of active trials terminated
• Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source NCT02167958 · started 2015 · scored riskier than 99% of active trials completed
• Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) NCT01518153 · started 2012 · scored riskier than 88% of active trials terminated
• Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia NCT01008462 · started 2010 · scored riskier than 39% of active trials completed
• Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies NCT01203722 · started 2010 · scored riskier than 88% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.